Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™

Orlo H. Clark; Jaffer Ajani; Al B. Benson; David Byrd; Gerard M. Doherty; Paul F. Engstrom; David S. Ettinger; John F. Gibbs; Martin J. Heslin; Fouad Kandeel; Anne Kessinger; Matthew H. Kulke; Larry Kvols; Albert A. Nemcek; John A. Olson; Thomas W. Ratliff; Leonard Saltz; David E. Schteingart; Manisha H. Shah; Stephen Shibata

doi:10.6004/jnccn.2006.0013

Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™

Orlo H. Clark, Jaffer Ajani, Al B. Benson, David Byrd, Gerard M. Doherty, Paul F. Engstrom, David S. Ettinger, John F. Gibbs, Martin J. Heslin, Fouad Kandeel, Anne Kessinger, Matthew H. Kulke, Larry Kvols, Albert A. Nemcek, John A. Olson, Thomas W. Ratliff, Leonard Saltz, David E. Schteingart, Manisha H. Shah, Stephen Shibata

Research output: Contribution to journal › Review article › peer-review

9 Scopus citations

Abstract

Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients.

Original language	English
Pages (from-to)	102-138
Number of pages	37
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	4
Issue number	2
DOIs	https://doi.org/10.6004/jnccn.2006.0013
State	Published - Feb 2006

Keywords

Carcinoma
Islet cell cancer
MEN-1
MEN-2
Multiple endocrine neoplasia
NCCN Clinical Practice Guidelines
Neuroendocrine tumors
Pheochromocytoma

Access to Document

10.6004/jnccn.2006.0013

Cite this

Clark, O. H., Ajani, J., Benson, A. B., Byrd, D., Doherty, G. M., Engstrom, P. F., Ettinger, D. S., Gibbs, J. F., Heslin, M. J., Kandeel, F., Kessinger, A., Kulke, M. H., Kvols, L., Nemcek, A. A., Olson, J. A., Ratliff, T. W., Saltz, L., Schteingart, D. E., Shah, M. H., & Shibata, S. (2006). Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™. JNCCN Journal of the National Comprehensive Cancer Network, 4(2), 102-138. https://doi.org/10.6004/jnccn.2006.0013

@article{bd1fc1aa114f40818eb10e444c5e44e4,

title = "Neuroendocrine tumors: Clinical Practice Guidelines in Oncology{\texttrademark}",

abstract = "Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients.",

keywords = "Carcinoma, Islet cell cancer, MEN-1, MEN-2, Multiple endocrine neoplasia, NCCN Clinical Practice Guidelines, Neuroendocrine tumors, Pheochromocytoma",

author = "Clark, {Orlo H.} and Jaffer Ajani and Benson, {Al B.} and David Byrd and Doherty, {Gerard M.} and Engstrom, {Paul F.} and Ettinger, {David S.} and Gibbs, {John F.} and Heslin, {Martin J.} and Fouad Kandeel and Anne Kessinger and Kulke, {Matthew H.} and Larry Kvols and Nemcek, {Albert A.} and Olson, {John A.} and Ratliff, {Thomas W.} and Leonard Saltz and Schteingart, {David E.} and Shah, {Manisha H.} and Stephen Shibata",

year = "2006",

month = feb,

doi = "10.6004/jnccn.2006.0013",

language = "English",

volume = "4",

pages = "102--138",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "2",

}

Clark, OH, Ajani, J, Benson, AB, Byrd, D, Doherty, GM, Engstrom, PF, Ettinger, DS, Gibbs, JF, Heslin, MJ, Kandeel, F, Kessinger, A, Kulke, MH, Kvols, L, Nemcek, AA, Olson, JA, Ratliff, TW, Saltz, L, Schteingart, DE, Shah, MH & Shibata, S 2006, 'Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™', JNCCN Journal of the National Comprehensive Cancer Network, vol. 4, no. 2, pp. 102-138. https://doi.org/10.6004/jnccn.2006.0013

TY - JOUR

T1 - Neuroendocrine tumors

T2 - Clinical Practice Guidelines in Oncology™

AU - Clark, Orlo H.

AU - Ajani, Jaffer

AU - Benson, Al B.

AU - Byrd, David

AU - Doherty, Gerard M.

AU - Engstrom, Paul F.

AU - Ettinger, David S.

AU - Gibbs, John F.

AU - Heslin, Martin J.

AU - Kandeel, Fouad

AU - Kessinger, Anne

AU - Kulke, Matthew H.

AU - Kvols, Larry

AU - Nemcek, Albert A.

AU - Olson, John A.

AU - Ratliff, Thomas W.

AU - Saltz, Leonard

AU - Schteingart, David E.

AU - Shah, Manisha H.

AU - Shibata, Stephen

PY - 2006/2

Y1 - 2006/2

N2 - Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients.

AB - Neuroendocrine tumors are relatively rare. An estimated 25,690 new cases of thyroid cancer will be diagnosed in the United States in 2005, accounting for approximately 1% of all malignancies. Neuroendocrine tumors can be broadly subdivided into tumors that are benign or malignant, functional (i.e., producing a syndrome of hormonal excess) or nonfunctional. The management of neuroendocrine tumors with surgical, medical, or radiation therapies is determined by the specific endocrine glands involved, aggressiveness and stage of the tumor, hormonal concentrations detected, and specific patient needs. These guidelines have been designed to address scenarios presented by 80% of patients and to avoid scenarios relevant to less than 5% of patients.

KW - Carcinoma

KW - Islet cell cancer

KW - MEN-1

KW - MEN-2

KW - Multiple endocrine neoplasia

KW - NCCN Clinical Practice Guidelines

KW - Neuroendocrine tumors

KW - Pheochromocytoma

UR - http://www.scopus.com/inward/record.url?scp=33646825000&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2006.0013

DO - 10.6004/jnccn.2006.0013

M3 - Review article

C2 - 16451769

AN - SCOPUS:33646825000

SN - 1540-1405

VL - 4

SP - 102

EP - 138

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 2

ER -

Neuroendocrine tumors: Clinical Practice Guidelines in Oncology™

Abstract

Keywords

Access to Document

Other files and links

Fingerprint

Cite this